Daniel Faga Sells 145,940 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the sale, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at approximately $17,132,541.86. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Daniel Faga also recently made the following trade(s):

• On Monday, March 25th, Daniel Faga sold 3,000 shares of AnaptysBio stock. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00.
• On Monday, January 8th, Daniel Faga sold 6,866 shares of AnaptysBio stock. The shares were sold at an average price of $21.81, for a total transaction of $149,747.46.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $21.38 on Thursday. The firm’s 50-day moving average is $24.00 and its 200-day moving average is $20.21. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $27.50. The company has a market cap of $572.13 million, a price-to-earnings ratio of -3.52 and a beta of -0.28.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ANAB shares. BTIG Research started coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 price objective for the company. Piper Sandler began coverage on shares of AnaptysBio in a research note on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective for the company. Stifel Nicolaus began coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Wedbush upgraded shares of AnaptysBio from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $20.00 to $34.00 in a report on Tuesday, March 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANAB. Woodline Partners LP increased its holdings in shares of AnaptysBio by 125.1% during the 2nd quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock worth $21,043,000 after purchasing an additional 574,987 shares during the period. First Light Asset Management LLC increased its holdings in shares of AnaptysBio by 56.4% during the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after purchasing an additional 446,372 shares during the period. Eventide Asset Management LLC bought a new position in shares of AnaptysBio during the 3rd quarter worth about $7,669,000. Millennium Management LLC increased its holdings in shares of AnaptysBio by 1,050.7% during the 4th quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company’s stock worth $10,004,000 after purchasing an additional 294,750 shares during the period. Finally, Palo Alto Investors LP increased its stake in AnaptysBio by 59.3% in the fourth quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company’s stock valued at $14,713,000 after acquiring an additional 255,658 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.